πŸ‡ΊπŸ‡Έ FDA
Patent

US 12202895

LILRB4 antibodies and uses thereof

granted A61KA61K2039/505A61K39/3955

Quick answer

US patent 12202895 (LILRB4 antibodies and uses thereof) held by The Board of Regents of the University of Texas System expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Jan 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
42
CPC classes
A61K, A61K2039/505, A61K39/3955, A61K45/06, A61K47/6849